Related Experiment Videos
Ecstasy-induced psychotic disorder: six-month follow-up study
M A Landabaso1, I Iraurgi, J M Jiménez-Lerma
1Drug Addiction Center, Barakaldo, Bizkaia, Spain.
European Addiction Research
|June 18, 2002
Summary
This study describes initial psychiatric symptoms in first-time ecstasy-induced psychotic disorder patients. Olanzapine treatment effectively reduced psychotic symptoms over six months with no significant side effects.
Area of Science:
- Psychiatry
- Pharmacology
- Toxicology
Background:
- Ecstasy (3,4-methylenedioxymethamphetamine) use can induce psychotic disorders.
- Characterizing these disorders and their treatment is crucial for clinical management.
Purpose of the Study:
- To detail the psychiatric symptoms of newly diagnosed ecstasy-induced psychotic disorder.
- To track symptom evolution over a six-month period.
Main Methods:
- An observational study followed 32 patients diagnosed with ecstasy-induced psychotic disorder.
- Psychiatric symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS), Hamilton Depression Rating Scale (HDRS), and Clinical Global Impression (CGI) at baseline and over six months.
- All participants received olanzapine treatment.
Main Results:
- A high incidence of severe psychiatric symptoms was noted at baseline.
- Psychotic symptoms (BPRS) significantly decreased within the first month of olanzapine treatment.
- Statistically significant clinical reductions in BPRS, HDRS, and CGI scores were observed over six months, with no major adverse effects.
Conclusions:
- Ecstasy-induced psychotic syndrome presents with severe psychotic symptoms, including positive and negative symptoms.
- Olanzapine demonstrated high efficacy and is suggested as a first-line treatment for this condition.